title: Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.
abstract: Combination therapies for leishmaniasis, including drugs and immunomodulators, are one approach to shorten treatment courses and to improve the treatment of complex manifestations of the disease. We evaluated a novel T-cell-epitope-enriched DNA vaccine candidate (LEISHDNAVAX) as host-directed immunotherapy in combination with a standard antileishmanial drug in experimental visceral leishmaniasis. Here we show that the DNA vaccine candidate can boost the efficacy of a single suboptimal dose of liposomal amphotericin B in C57BL/6 mice.
authors.affiliation: Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom karin.seifert@lshtm.ac.uk.
authors.forename: Karin
authors.initials: K
authors.lastname: Seifert
authors.affiliation: Mologen AG, Berlin, Germany.
authors.forename: Christiane
authors.initials: C
authors.lastname: Juhls
authors.affiliation: Animal Health and Veterinary Laboratories Agency, New Haw, Surrey, United Kingdom School of Veterinary Medicine, University of Surrey, Guildford, Surrey, United Kingdom.
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Salguero
authors.affiliation: Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
authors.forename: Simon L
authors.initials: SL
authors.lastname: Croft
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use*; D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D005260:Female; D007167:Immunotherapy / Q000379:methods; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D019444:Vaccines, DNA / Q000627:therapeutic use*
chemical_list: D000981:Antiprotozoal Agents; D019444:Vaccines, DNA; C068538:liposomal amphotericin B; D000666:Amphotericin B